We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Evaluating Safety Risks of Tramadol for Pediatric Patients
FDA Evaluating Safety Risks of Tramadol for Pediatric Patients
The FDA is evaluating the potential risks of prescribing tramadol for children 17 years and younger because it may cause slowed or difficult breathing. The opioid drug is not approved for use in children, but is being prescribed “off-label.”